A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer

2018

PHARMACOLOGICAL RESEARCH

A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer

01 Pubblicazione su rivista

Cevatemre B., Erkısa M., Aztopal N., Karakas D., Alper P., Tsimplouli C., Sereti E., Dimas K., Armutak E. I. I., Gurevin E. G., Uvez A., Mori M., Berardozzi S., Ingallina C., D'Acquarica I., Botta B., Ozpolat B., Ulukaya E.

DOI: 10.1016/j.phrs.2017.11.027

ISSN: 1043-6618

Several natural products have been suggested as effective agents for the treatment of cancer. Given the important role of CSCs (Cancer Stem Cells) in cancer, which is a trendy hypothesis, it is worth investigating the effects of pristimerin on CSCs as well as on the other malignant cells (MCF-7 and MDA-MB-231) of breast cancer. The anti-growth activity of pristimerin against MCF-7 and MCF-7s (cancer stem cell enriched population) cells was investigated by real time viability monitorization (xCELLigence System®) and ATP assay, respectively. Mode of cell death was evaluated using electron and fluorescence microscopies, western blotting (autophagy, apoptosis and ER-stress related markers) and flow cytometry (annexin-V staining, caspase 3/7 activity, BCL-2 and PI3K expressions). Pristimerin showed an anti-growth effect on cancer cells and cancer stem cells with IC50 values ranging at 0.38-1.75μM. It inhibited sphere formation at relatively lower doses (

cytoplasmic vacuolation endoplasmic reticulum stress mammosphere triterpenoid